News for Healthier Living

New Study from Caris Life Sciences Validates Optimal Sequencing in Informing Therapy Choices for Breast Cancer Subgroups

Caris Life Sciences(r) (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published results in Breast Cancer Research comparing the effectiveness and optimal sequencing of two antibody-drug conjugates, trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), in HER2-negative breast cancer patients.

August 13, 2025


August 14 2025

August 13 2025

August 12 2025

August 11 2025

August 10 2025

August 9 2025

August 8 2025

August 7 2025

August 6 2025

August 5 2025

August 4 2025

August 3 2025

August 2 2025

August 1 2025